Strategic partnership to advance early disease detection with cutting-edge optical technology
In a move set to redefine non-invasive disease detection, Remidio, a global leader in AI-powered ophthalmic solutions, has strategically invested in Occuity, a pioneering UK-based developer of handheld, optical screening and monitoring devices that are non-contact and require no consumables.
The investment marks a strategic move to position Remidio at the forefront of non-invasive systemic disease screening, building on its global leadership in AI-driven ophthalmic solutions.
Remidio and Occuity’s partnership will begin with the integration of technologies to co-develop a comprehensive myopia screening solution, addressing India’s growing myopia epidemic. By 2050, nearly 48 per cent of urban children are expected to be affected, with 20 per cent experiencing rapid progression and around 4% facing complications that could lead to permanent vision loss.
A key part of this solution is the introduction of India’s first-of-its-kind handheld, non-invasive, and highly accurate axial length measurement device for myopia detection and monitoring. This innovation eliminates the need for complex and expensive eye exams, making early diagnosis more accessible—particularly for children.
With Remidio’s deep distribution networks and proven ability to deploy AI-powered diagnostics at scale, this collaboration will enable widespread, early myopia detection for millions of children across India.
The collaboration will also introduce a novel non-contact, handheld device for accurately assessing corneal thickness—critical for managing glaucoma patients and evaluating suitability for interventions such as LASIK. This innovation will enhance Remidio’s widely used Comprehensive Eye Clinic in a Bag, further extending access to comprehensive eye disease screening.
Leveraging Remidio’s expertise in AI-powered diagnostics and scalable manufacturing, this collaboration will accelerate the development and deployment of Occuity’s non-contact, handheld screening solutions globally.
This includes the Occuity Indigo—an optical glucose meter designed to measure glucose levels through a simple eye scan, eliminating the need for painful finger-prick tests currently endured by over 100 million diabetes patients in India.
"We believe that non-invasive diagnostics are the future of healthcare, particularly for large-scale public health challenges like diabetes and myopia," said Dr Anand Sivaraman, CEO, Remidio. "Occuity’s technology aligns perfectly with our mission to democratise high-quality screening and management, making preventive healthcare more accessible than ever before."
Dr Dan Daly, CEO and Co-Founder, Occuity, added, "Remidio’s deep expertise in the design, development and manufacturing of AI-integrated ophthalmic devices and their strong presence in the global ophthalmology market, including India, make them an ideal partner to expand the reach of our breakthrough non-contact screening devices. Their investment is a testament to our shared vision of transforming early disease detection and driving better patient outcomes globally."
